Vega Life Sciences Warning Letter Shows Difficulty Of Applying Drug GMPs To API Solvent Recyclers

Recycling offers economic and environmental benefits, but risks introducing potentially carcinogenic impurities. Company barred from US market.

Warning hazard sign and signage man falling
a point of no return • Source: Shutterstock

A recent US Food and Drug Administration warning letter provides more insight into how difficult it will be for active pharmaceutical ingredient manufacturers to retain the economic and environmental benefits of solvent recycling without risking the introduction of potentially carcinogenic impurities such as nitrosamines into drug products.

The warning letter the agency sent on 17 June to Vega Life Sciences Private Ltd., an API solvent recycler near Hyderabad, India, highlighted deficiencies observed during a 25-28 November...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Compliance

More from Pink Sheet

Canada Cuts Red Tape With Single Ethics Review For Trials

 

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.